Hanqing Zeng

Hanqing Zeng

Auto-generated profile, based on publicly available information

Hanqing Zeng

Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, No.288, Tian-Wen Road, Chongqing 40000, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2025 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
ZCZhe Chen
Zhe Chen
FWFeng Wu
Feng Wu
YLYan Li
Yan Li
LLLei Li
Lei Li
YLYufei Lei
Yufei Lei
YHYu Hou
Yu Hou
Hematopoietic stem cells (HSCs) are susceptible to replication stress, which is a major contributor to HSC defects in Fanconi anemia (FA). Here, we report that HSCs relax the global chromatin by downregulating the expression of a chromatin architectural protein, DEK, in response to replication stress. DEK is abnormally accumulated in bone marrow (BM) CD34+ cells from patients with FA and in Fancd2-deficient HSCs. DEK haploinsufficiency promotes chromatin relaxation, replication stress relief, and function recovery of Fancd2-deficient HSCs. Furthermore, inhibition of DEK restores the proliferation of FA CD34+ cells in vitro and enhances their engraftment in vivo. Mechanistically, the activating transcription factor 2 (ATF2), specifically phosphorylated ATF2 at Thr69/71, was identified as a promoter of DEK transcription. Fancd2 deficiency results in p38 hyperphosphorylation, which in turn phosphorylates ATF2 at Thr69/71, leading to DEK accumulation in HSCs. In conclusion, our findings establish a functional link between chromatin relaxation and replication stress tolerance in HSCs and highlight DEK as a target for FA.

27 March 2025 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
BLBingqing Luo
Bingqing Luo
XTXiaoyan Tan
Xiaoyan Tan
YZYanfang Zhang
Yanfang Zhang
XHXiao Hu
Xiao Hu
HZHanqing Zeng
Hanqing Zeng
KZKang Zhou
Kang Zhou
Background: Effective treatment options are limited for elderly patients with acute myeloid leukemia (AML). A prospective phase II study was conducted to investigate the safety and efficacy of pegylated liposomal doxorubicin (PLD) combined with low-dose cytarabine (LDAC) and granulocyte colony-stimulating factor (G-CSF) in newly diagnosed older and unfit AML patients. Methods: Twenty-two patients were enrolled and deemed evaluable. The study included one cycle of induction and four cycles of consolidation, followed by maintenance therapy. Results: The median age of enrolled patients was 71.5 years (range, 63 to 82 years), and 16 patients (72.7%) were over 70 years of age. The overall response rate (ORR) was 77.3% (n = 17) and the complete remission (CR)/complete remission with incomplete recovery (CRi) rate was 63.6% (n = 14) after the first induction cycle. With a median follow-up of 12.4 months, eight patients (57.1%) relapsed, with a median time to relapse of 12.3 months. The median duration of response (DOR) was 11.9 months (95% CI, 6.4 to NA months), the median overall survival (OS) was 15 months (95% CI, 8.4 to 21.6 months), and the median progression-free survival (PFS) was 7.5 months (95% CI, 4.6 to 15.1 months). Common grade 3 or greater adverse events included febrile neutropenia (77.8%) and infection (63.6%), with pneumonia being the most common (10, 45.5%). There was one death (4.5%) within 30 days. Conclusion: The combination of PLD, LDAC, and G-CSF is well-tolerated and exhibits high rates of CR/CRi and low early mortality, providing an attractive treatment option for newly diagnosed elderly and unfit AML patients.

1 July 2025 in Transplantation and Cellular Therapy
Verified
Journal Article
Closed access
FLFenglian Luo
Fenglian Luo
ZLZhiming Luo
Zhiming Luo
YLYun Luo
Yun Luo
HZHanqing Zeng
Hanqing Zeng
YCYing Chen
Ying Chen
CCChun Cao
Chun Cao